AR032173A1 - Cripto proteinas y sus variantes como efectores linfocitarios contra el cancer - Google Patents
Cripto proteinas y sus variantes como efectores linfocitarios contra el cancerInfo
- Publication number
- AR032173A1 AR032173A1 ARP010104025A ARP010104025A AR032173A1 AR 032173 A1 AR032173 A1 AR 032173A1 AR P010104025 A ARP010104025 A AR P010104025A AR P010104025 A ARP010104025 A AR P010104025A AR 032173 A1 AR032173 A1 AR 032173A1
- Authority
- AR
- Argentina
- Prior art keywords
- sequences
- seq
- polynucleotides
- encoded
- polynucleotide
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 8
- 108091033319 polynucleotide Proteins 0.000 abstract 8
- 239000002157 polynucleotide Substances 0.000 abstract 8
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen y reivindican polinucleotidos y aislados de polipéptidos que comprenden secuencias de aminoácidos codificados por dichos polinucleotidos, aplicables en el diagnostico y terapia del cáncer particularmente del cáncer de pulmon, del colon y colorectal. Dichas secuencias de polinucleotidos se seleccionan del grupo consistente de: (a) secuencias formadas por al menos 20 residuos contiguos de una secuencia proporcionada en SEQ ID NO: 1 o 3, sin ser la SEQ ID NO: 1 completa o la SEQ ID NO: 3 completa; (b) secuencias que comprenden SEQ ID NO: 1 o al menos 20 residuos contiguos de la misma y un polinucleotido que codifica una molécula de fusion heterologo; (c) variantes degeneradas de las secuencias de (a) y (b) anteriores. Dichas secuencias de aminoácidos se seleccionan del grupo consistente de: (a) secuencias codificadas por un polinucleotido segun la reivindicacion 1; y (b) secuencias que tienen una identidad de al menos el 70% con una secuencia codificada por un polinucleotido segun la reivindicacion 1; y (c) secuencias que tienen una identidad de al menos el 90% con una secuencia codificada por un polinucleotido segun la reivindicacion 1. Y además - vectores de expresion operables que comprenden dichos polinucleotidos, células transfectadas y células transformadas con dichos vectores y composiciones para el diagnostico, prevencion y/o los tratamientos de las enfermedades mencionadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0020953.6A GB0020953D0 (en) | 2000-08-24 | 2000-08-24 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032173A1 true AR032173A1 (es) | 2003-10-29 |
Family
ID=9898284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104025A AR032173A1 (es) | 2000-08-24 | 2001-08-23 | Cripto proteinas y sus variantes como efectores linfocitarios contra el cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7439320B2 (es) |
| EP (1) | EP1311678A2 (es) |
| JP (1) | JP2004506441A (es) |
| KR (1) | KR20030045041A (es) |
| CN (1) | CN1471579A (es) |
| AR (1) | AR032173A1 (es) |
| AU (1) | AU2001295498A1 (es) |
| BR (1) | BR0113491A (es) |
| CA (1) | CA2420087A1 (es) |
| CZ (1) | CZ2003537A3 (es) |
| GB (1) | GB0020953D0 (es) |
| HU (1) | HUP0302824A2 (es) |
| IL (1) | IL154533A0 (es) |
| MX (1) | MXPA03001634A (es) |
| NO (1) | NO20030823L (es) |
| NZ (1) | NZ524344A (es) |
| PL (1) | PL363005A1 (es) |
| WO (1) | WO2002016413A2 (es) |
| ZA (1) | ZA200301436B (es) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR395801A0 (en) * | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| PT1390389E (pt) | 2001-04-26 | 2009-04-03 | Biogen Idec Inc | Anticorpos que bloqueiam o cripto e as utilizações dos mesmos |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| EP1494693B1 (en) * | 2002-03-22 | 2010-12-08 | Biogen Idec MA Inc. | Cripto-specific antibodies |
| EP1641827A2 (en) | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| EP1753463A2 (en) | 2004-06-01 | 2007-02-21 | Genentech, Inc. | Antibody drug conjugates and methods |
| US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| JP2008526234A (ja) | 2005-01-05 | 2008-07-24 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ結合分子 |
| US8527510B2 (en) | 2005-05-23 | 2013-09-03 | Monster Worldwide, Inc. | Intelligent job matching system and method |
| US8195657B1 (en) | 2006-01-09 | 2012-06-05 | Monster Worldwide, Inc. | Apparatuses, systems and methods for data entry correlation |
| US8600931B1 (en) | 2006-03-31 | 2013-12-03 | Monster Worldwide, Inc. | Apparatuses, methods and systems for automated online data submission |
| US12314907B2 (en) | 2006-03-31 | 2025-05-27 | Monster Worldwide, Inc. | Apparatuses, methods and systems for automated online data submission |
| EP2021510A2 (en) * | 2006-04-28 | 2009-02-11 | Biogen Idec MA Inc. | Composition and methods for the detection of cripto-3 |
| WO2008040759A1 (en) * | 2006-10-03 | 2008-04-10 | Pharmexa A/S | Method for down-regulation of cripto |
| US8645817B1 (en) * | 2006-12-29 | 2014-02-04 | Monster Worldwide, Inc. | Apparatuses, methods and systems for enhanced posted listing generation and distribution management |
| US9779390B1 (en) | 2008-04-21 | 2017-10-03 | Monster Worldwide, Inc. | Apparatuses, methods and systems for advancement path benchmarking |
| WO2011031870A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| EP2579897A1 (en) | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| US8679767B2 (en) | 2011-05-12 | 2014-03-25 | Genentech, Inc. | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides |
| SG11201401406YA (en) | 2011-10-14 | 2014-05-29 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP2906251B1 (en) | 2012-10-12 | 2017-09-27 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| NZ707486A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
| TR201808051T4 (tr) | 2012-10-12 | 2018-06-21 | Adc Therapeutics Sa | Pirrolobenzodiazepin antikor konjugatları. |
| CA2941485C (en) | 2012-10-12 | 2018-06-12 | Philip Wilson Howard | Pyrrolobenzodiazepines and conjugates thereof |
| JP6392763B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ | ピロロベンゾジアゼピン−抗体結合体 |
| EA031585B1 (ru) | 2012-12-21 | 2019-01-31 | Медимьюн Лимитед | Пирролобензодиазепины и их конъюгаты |
| WO2014096365A1 (en) | 2012-12-21 | 2014-06-26 | Spirogen Sàrl | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| MX364330B (es) | 2013-03-13 | 2019-04-23 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| US20160031887A1 (en) | 2013-03-13 | 2016-02-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| KR102057755B1 (ko) | 2013-03-13 | 2019-12-19 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
| CN105636612B (zh) | 2013-08-12 | 2020-01-14 | 基因泰克公司 | 抗体-药物缀合物及使用和治疗方法 |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
| EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| RU2689388C1 (ru) | 2013-12-16 | 2019-05-28 | Дженентек, Инк. | Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами |
| CN105828840B (zh) | 2013-12-16 | 2020-08-04 | 基因泰克公司 | 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法 |
| EA201691023A1 (ru) | 2013-12-16 | 2016-10-31 | Дженентек, Инк. | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством |
| US20170330153A1 (en) | 2014-05-13 | 2017-11-16 | Monster Worldwide, Inc. | Search Extraction Matching, Draw Attention-Fit Modality, Application Morphing, and Informed Apply Apparatuses, Methods and Systems |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| KR20170052600A (ko) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | 시스테인 가공된 항체 및 콘주게이트 |
| CN106714844B (zh) | 2014-09-12 | 2022-08-05 | 基因泰克公司 | 蒽环类二硫化物中间体、抗体-药物缀合物和方法 |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| MX2017003523A (es) | 2014-09-17 | 2017-11-08 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas. |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| MX379396B (es) | 2014-11-25 | 2025-03-11 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepina y anticuerpo. |
| JP6752204B2 (ja) | 2014-12-03 | 2020-09-09 | ジェネンテック， インコーポレイテッド | 四級アミン化合物及びその抗体−薬物コンジュゲート |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
| US10691773B2 (en) | 2015-12-30 | 2020-06-23 | General Electric Company | Cell processing techniques |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN114028549A (zh) * | 2016-02-19 | 2022-02-11 | 伊玛提克斯生物技术有限公司 | 用于nhl和其他癌症免疫治疗的新型肽和肽组合物 |
| CN108700598A (zh) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
| EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| CN109476648B (zh) | 2016-06-06 | 2022-09-13 | 豪夫迈·罗氏有限公司 | 司维司群抗体-药物缀合物和使用方法 |
| CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| WO2018146189A1 (en) | 2017-02-08 | 2018-08-16 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| RS63502B1 (sr) | 2017-04-18 | 2022-09-30 | Medimmune Ltd | Konjugati pirolobenzodiazepina |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| AU2018285562B2 (en) | 2017-06-14 | 2024-01-18 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
| HRP20220311T1 (hr) | 2017-08-18 | 2022-05-13 | Medimmune Limited | Konjugati pirolobenzodiazepina |
| IL302943A (en) | 2017-09-20 | 2023-07-01 | Ph Pharma Co Ltd | Thylanstatin analogs |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| CN113056287A (zh) | 2018-10-24 | 2021-06-29 | 豪夫迈·罗氏有限公司 | 缀合的化学降解诱导剂及使用方法 |
| JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック， インコーポレイテッド | Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| EP3938372B1 (en) | 2019-03-15 | 2023-10-25 | MedImmune Limited | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| KR20240095442A (ko) | 2021-11-03 | 2024-06-25 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 항체의 특이적 접합 |
| JP2026502860A (ja) | 2022-12-23 | 2026-01-27 | ジェネンテック， インコーポレイテッド | セレブロン分解剤コンジュゲートおよびその使用 |
| CN121263210A (zh) | 2023-04-17 | 2026-01-02 | 沛科生物公司 | 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体 |
| WO2026006689A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Bcl-xl degrader antibody conjugates and uses thereof |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256643A (en) * | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| US5264557A (en) * | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
| US5633147A (en) * | 1994-03-08 | 1997-05-27 | Human Genome Sciences, Inc. | Transforming growth factor αH1 |
| US6270777B1 (en) * | 1996-12-20 | 2001-08-07 | University Technologies International Inc. | Conserved metalloprotease epitopes |
| US5834399A (en) * | 1997-12-22 | 1998-11-10 | Eastman Kodak Company | Subbing layer for dye-donor element used in thermal dye transfer |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| US6387888B1 (en) * | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
| US6537552B1 (en) * | 1999-10-19 | 2003-03-25 | Iowa State University Research Foundation | Vaccine adjuvant |
| AU2001264559A1 (en) * | 2000-06-05 | 2001-12-17 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| GB0219776D0 (en) * | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
-
2000
- 2000-08-24 GB GBGB0020953.6A patent/GB0020953D0/en not_active Ceased
-
2001
- 2001-08-20 CA CA002420087A patent/CA2420087A1/en not_active Abandoned
- 2001-08-20 WO PCT/EP2001/009646 patent/WO2002016413A2/en not_active Ceased
- 2001-08-20 MX MXPA03001634A patent/MXPA03001634A/es not_active Application Discontinuation
- 2001-08-20 HU HU0302824A patent/HUP0302824A2/hu unknown
- 2001-08-20 JP JP2002521508A patent/JP2004506441A/ja active Pending
- 2001-08-20 US US10/362,597 patent/US7439320B2/en not_active Expired - Fee Related
- 2001-08-20 AU AU2001295498A patent/AU2001295498A1/en not_active Abandoned
- 2001-08-20 NZ NZ524344A patent/NZ524344A/en unknown
- 2001-08-20 KR KR10-2003-7002701A patent/KR20030045041A/ko not_active Withdrawn
- 2001-08-20 EP EP01976131A patent/EP1311678A2/en not_active Withdrawn
- 2001-08-20 BR BR0113491-4A patent/BR0113491A/pt not_active IP Right Cessation
- 2001-08-20 IL IL15453301A patent/IL154533A0/xx unknown
- 2001-08-20 CN CNA018177336A patent/CN1471579A/zh active Pending
- 2001-08-20 CZ CZ2003537A patent/CZ2003537A3/cs unknown
- 2001-08-20 PL PL01363005A patent/PL363005A1/xx unknown
- 2001-08-23 AR ARP010104025A patent/AR032173A1/es not_active Application Discontinuation
-
2003
- 2003-02-21 ZA ZA200301436A patent/ZA200301436B/xx unknown
- 2003-02-21 NO NO20030823A patent/NO20030823L/no not_active Application Discontinuation
- 2003-04-04 US US10/407,481 patent/US20040138112A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7439320B2 (en) | 2008-10-21 |
| NO20030823L (no) | 2003-04-23 |
| WO2002016413A8 (en) | 2003-02-06 |
| JP2004506441A (ja) | 2004-03-04 |
| HUP0302824A2 (hu) | 2005-05-30 |
| WO2002016413A2 (en) | 2002-02-28 |
| CN1471579A (zh) | 2004-01-28 |
| MXPA03001634A (es) | 2004-09-10 |
| WO2002016413A3 (en) | 2002-12-05 |
| NO20030823D0 (no) | 2003-02-21 |
| PL363005A1 (pl) | 2004-11-15 |
| NZ524344A (en) | 2004-07-30 |
| US20040138112A1 (en) | 2004-07-15 |
| ZA200301436B (en) | 2004-05-21 |
| KR20030045041A (ko) | 2003-06-09 |
| GB0020953D0 (en) | 2000-10-11 |
| AU2001295498A1 (en) | 2002-03-04 |
| CZ2003537A3 (cs) | 2003-09-17 |
| US20040054142A1 (en) | 2004-03-18 |
| EP1311678A2 (en) | 2003-05-21 |
| IL154533A0 (en) | 2003-09-17 |
| BR0113491A (pt) | 2003-06-24 |
| CA2420087A1 (en) | 2002-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032173A1 (es) | Cripto proteinas y sus variantes como efectores linfocitarios contra el cancer | |
| AR014514A1 (es) | Un polinucleotido aislado; un polipeptido aislado codificado por dicho polinucleotido; un vector de expresion que comprende dicho polinucleotido; unacelula transformada con dicho vector de expresion; una composicion farmaceutica y una vacuna que comprenden el polipeptido para el tratamiento de cance | |
| MX2024015050A (es) | L-asparaginasa modificada | |
| DK289688D0 (da) | Ekspression af proapolipoprotein a-i. | |
| CY1113379T1 (el) | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν | |
| CA2370289A1 (en) | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides | |
| CO5700788A2 (es) | Composiciones y metodos para inmunoterapia especifica de wt1 | |
| PE20240915A1 (es) | Composiciones y metodos para tratar la enfermedad de fabry | |
| AR020066A1 (es) | Un polipeptido purificado, util para prevenir la tuberculosis y las composiciones farmaceuticas que contienen dichos polipeptidos y los polinucleotidos quelos codifican | |
| AR002742A1 (es) | Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn | |
| AR010337A1 (es) | Acido nucleico aislado, molecula de acido nucleico, sonda, vector de expresion recombinante, celula, metodo para producir un polipeptido de h.pylori, metodo para detectar la presencia de un acido nucleico helicobacter, polipeptido de h.pylori aislado, proteina de fusion, formulacion para vacuna | |
| DK1237915T3 (da) | Polynucleotid, som kodet for polypeptidet RG1 | |
| PE20001287A1 (es) | Composicion farmaceutica que contiene fragmentos de adn codificador de una proteina antigenica con efecto antitumoral | |
| AR015393A1 (es) | Molecula de polinucleotido aislada, molecula de oligonucleotido que la hibrida, vector de expresion recombinante, celula hospedadora transformada,polipeptido aislado, procedimiento para prepararlo, analogos o derivados del mismo, vacuna que comprende los anteriores, vacuna de combinacion, procedimie | |
| PE20061441A1 (es) | Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia | |
| HRP20090119T3 (en) | Use of soluble t-cadherin for the treatment of metabolic disorders | |
| AR077577A2 (es) | Polipeptidos relacionados con cancer de colon humano, polinucleotidos que lo codifican, vector, usos y composiciones farmaceuticas | |
| DE60120187T2 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
| DK1947175T3 (da) | Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf | |
| AR029130A1 (es) | Gen enzimatico y sus productos de expresion | |
| WO2024123895A3 (en) | A molecular switch to tune the avidity of immune cells to their target | |
| ATE544779T1 (de) | Neue, die migration dendritischer zellen induzierende polypeptide, sowie medikamente und pharmazeutische zusammensetzungen, die diese enthalten | |
| AR018100A1 (es) | Polipeptidos que comprenden una parte inmunogenica de un antigeno de m.tuberculosis soluble, y moleculas de adn que codifican dichos polipeptidos, losvectores de expresion que comprenden dichas moleculas de adn, las celulas huesped transformadas con dichos vectores, las composiciones farmaceuticas, | |
| AR133989A1 (es) | Miniproteínas, conjugados y usos de las mismas | |
| WO2007069247A3 (en) | Polynucleotides and polypeptide of human kv1.3, compositions comprising same and methods of using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |